NEW YORK, March 12 – Abbott Laboratories and Millennium Pharmaceuticals said Monday that they agreed to enter a five-year, $250 million strategic alliance to jointly discover and develop obesity and diabetes drugs.

Under the terms of the agreement, Abbott of Abbott Park, Ill., said it would purchase $250 million worth of Millennium’s common stock. Abbott will acquire $50 million at the closing of the deal and the remaining $200 million over the next two years. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.